CA3231697A1 - Polymorphs as erbb inhibitors - Google Patents

Polymorphs as erbb inhibitors Download PDF

Info

Publication number
CA3231697A1
CA3231697A1 CA3231697A CA3231697A CA3231697A1 CA 3231697 A1 CA3231697 A1 CA 3231697A1 CA 3231697 A CA3231697 A CA 3231697A CA 3231697 A CA3231697 A CA 3231697A CA 3231697 A1 CA3231697 A1 CA 3231697A1
Authority
CA
Canada
Prior art keywords
morphic
compound
xrpd
radiation
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3231697A
Other languages
English (en)
French (fr)
Inventor
Wu-Yan Zhang
Reza FOROUGHI
Siyi Jiang
Meiqi LI
Juanjuan SHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Black Diamond Therapeutics Inc
Original Assignee
Black Diamond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Diamond Therapeutics Inc filed Critical Black Diamond Therapeutics Inc
Publication of CA3231697A1 publication Critical patent/CA3231697A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3231697A 2021-09-21 2022-09-21 Polymorphs as erbb inhibitors Pending CA3231697A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163246451P 2021-09-21 2021-09-21
US63/246,451 2021-09-21
PCT/US2022/044232 WO2023049168A1 (en) 2021-09-21 2022-09-21 Polymorphs as erbb inhibitors

Publications (1)

Publication Number Publication Date
CA3231697A1 true CA3231697A1 (en) 2023-03-30

Family

ID=83691602

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3231697A Pending CA3231697A1 (en) 2021-09-21 2022-09-21 Polymorphs as erbb inhibitors

Country Status (10)

Country Link
US (1) US20240425492A1 (cg-RX-API-DMAC10.html)
EP (1) EP4405350A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024534517A (cg-RX-API-DMAC10.html)
KR (1) KR20240099193A9 (cg-RX-API-DMAC10.html)
CN (1) CN119110799A (cg-RX-API-DMAC10.html)
AU (1) AU2022352658A1 (cg-RX-API-DMAC10.html)
CA (1) CA3231697A1 (cg-RX-API-DMAC10.html)
IL (1) IL311354A (cg-RX-API-DMAC10.html)
MX (1) MX2024003475A (cg-RX-API-DMAC10.html)
WO (1) WO2023049168A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
WO2024179451A1 (zh) * 2023-03-02 2024-09-06 江苏康缘药业股份有限公司 一种炔基取代的喹唑啉化合物的晶型、其制备方法和应用
WO2025038731A1 (en) * 2023-08-15 2025-02-20 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
CN122580302A (zh) * 2023-12-21 2026-08-14 黑钻治疗公司 Erbb抑制剂的固体形式
WO2025137421A1 (en) * 2023-12-21 2025-06-26 Black Diamond Therapeutics, Inc. Compositions comprising alkyne substituted quinazoline derivatives and related uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) * 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
MX2023004998A (es) * 2020-11-02 2023-05-12 Black Diamond Therapeutics Inc Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.

Also Published As

Publication number Publication date
IL311354A (en) 2024-05-01
EP4405350A1 (en) 2024-07-31
KR20240099193A9 (ko) 2025-12-10
MX2024003475A (es) 2024-04-05
KR20240099193A (ko) 2024-06-28
CN119110799A (zh) 2024-12-10
AU2022352658A1 (en) 2024-03-21
JP2024534517A (ja) 2024-09-20
US20240425492A1 (en) 2024-12-26
WO2023049168A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
US20240425492A1 (en) Polymorphs as erbb inhibitors
US12152034B2 (en) FGFR inhibitors and methods of making and using the same
US20240217922A1 (en) Modulators of sortilin activity
US20260125374A1 (en) Pi3k-alpha inhibitors and methods of making and using the same
CN118574830A (zh) 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
MX2012009894A (es) Inhibidores dimericos de iap.
JP2025505812A (ja) 化合物及びその用途
BR112019027545A2 (pt) compostos de pirrolotriazina 7-substituídos ou sais farmaceuticamente aceitáveis dos mesmos, e métodos e preparação e usos dos mesmos
US11654144B2 (en) Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1- yl)pyrimidin-4-amine and new salts
US20250026773A1 (en) Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof
EP3390369A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
WO2025137421A1 (en) Compositions comprising alkyne substituted quinazoline derivatives and related uses
CN114728875A (zh) 金属盐及其用途
WO2020198067A1 (en) Pkm2 modulators and methods for their use
JP6595011B2 (ja) 新規ホスホジエステラーゼ5阻害剤とその使用
WO2025137424A1 (en) Solid forms of an erbb inhibitor
CN116332960A (zh) 一种哒嗪类化合物、其药物组合物及应用
CA3160903C (en) Thiazololactam compound as erk inhibitor and use thereof
WO2025226822A2 (en) Forms and salts of 6-aza-quinoline derivatives and related uses
CN117263950A (zh) 一种哒嗪类化合物、其药物组合物及应用
WO2025128831A1 (en) Combinations comprising alkyne substituted quinazoline derivatives and their use in the treatment of cancer
WO2025117550A1 (en) Solid state forms of a quinoxaline derivative useful in the treatment of cancer
HK40077267A (en) Metal salts and uses thereof
HK40060068B (en) Use of quinazoline derivative in preparation of drug for treating nasopharyngeal carcinoma

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240917

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240917

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240917

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250704

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250704

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260702